Výsledky vyhledávání - "Lindsey Millard"

Enzymatic Characterisation of USP7 Deubiquitinating activity and Inhibition

Autor: Kevin Hudson, Richard Mott, Richard A. Ward, Jonathan D. Wrigley, Stephen W. Peters, Ian M. Hardern, Lindsey Millard, Thorsten Nowak, Peter B. Simpson, Kay Eckersley, Michael Walters

Publikováno v: Cell Biochemistry and Biophysics. 60:99-111

USP7 (HAUSP) is a deubiquitinating enzyme, which plays a crucial role in regulating the levels of the p53 tumour suppressor protein, through its ability to prevent the proteasomal degradation of the Ubiquitin ligase for p53, Hdm2. Supporting evidence

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe0167479c489d7167ca78100a9638f5
https://doi.org/10.1007/s12013-011-9186-4

Zobrazit plný text záznamu

Abstract CT159: Investigation of the absorption, metabolism, excretion, and mass balance of [14C]-pacritinib in healthy subjects: a phase I study

Autor: James P. Dean, Jack W. Singer, Sherri Amberg, Huafeng Zhou, Lindsey Millard, Suliman Al-Fayoumi

Publikováno v: Cancer Research. 76:CT159-CT159

Introduction: Dysregulation in tyrosine kinase signaling has been implicated in development of hematologic malignancies including myelofibrosis and lymphomas. Pacritinib is an oral kinase inhibitor with specificity for JAK2, FLT3, CSF1R, and IRAK1. I

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::876af67c9d8ca978953a741a6d2e8d5d
https://doi.org/10.1158/1538-7445.am2016-ct159

Zobrazit plný text záznamu

Clinical Pharmacology Profile of Pacritinib (PAC), a Novel JAK2/FLT3 Inhibitor

Autor: Suliman Al-Fayoumi, Huafeng Zhou, James P. Dean, Mary S. Campbell, Sherri Amberg, Lindsey Millard

Publikováno v: Blood. 126:5178-5178

Introduction: PAC is a kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CFS1R that does not inhibit JAK1. PAC has demonstrated activity in phase (Ph) 1-3 clinical studies. Nonclinical and clinical pharmacokinetic (PK) and pharmacodynamic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1e35c0d7f30aec9fe409d09a58080d66
https://doi.org/10.1182/blood.v126.23.5178.5178

Zobrazit plný text záznamu

Abstract 4043: Characterization of the enzymatic activity, biochemical requirements and inhibition of deubiquitinating enzymes, a novel oncology target class

Autor: Kay Eckersley, Helen Plant, Peter B. Simpson, David M. Andrews, Kevin Hudson, Lindsey Millard, Marian Preston, Ian M. Hardern, Thorsten Nowak, Jonathan D. Wrigley

Publikováno v: Cancer Research. 71:4043-4043

Deubiquitinating enzymes (DUBs) represent promising opportunities for therapeutic intervention in oncology, and this study reports key information about the catalytic activity, assaying and inhibition of this novel enzyme class. The DUBs are protease

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b7d38e04698582a133ffbd3b975adb63
https://doi.org/10.1158/1538-7445.am2011-4043

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání